Among patients in high-risk group, reduced immune infiltration suggests potential benefits from combination immunotherapies, such as PD-1/PD-L1 inhibitors, targeted suppression of inhibitory cytokines, cancer vaccines, or autologous immune cell infusions, may enhance antitumor efficacy (50). This evidence concerns the gene CD274 and cancer.